Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation.

L H Boise, C B Thompson
Author Information
  1. L H Boise: Gwen Knapp Center for Lupus and Immunology Research, Department of Medicine, University of Chicago, IL 60637, USA.

Abstract

Programmed cell death or apoptosis provides an irreversible mechanism for the elimination of excess or damaged cells. Several recent studies have implicated the activation of the interleukin 1beta-converting enzyme/Ced-3 (ICE/Ced-3) family of proteases as the "point of no return" in apoptotic cell death, while others have suggested that loss of mitochondrial membrane potential (delta psi(m)) is the ultimate determinant of cell death. The temporal relationship of these two events during apoptosis and the role of Bcl-2 proteins in inhibiting these steps has not been defined. To examine these issues, control and Bcl-x(L)-transfected Jurkat T cells were treated with Fas antibodies in the presence and absence of the ICE protease inhibitor zVAD-FMK. ICE/Ced-3 protease activity was monitored by following the cleavage of poly(ADP-ribose) polymerase (PARP) and delta psi(m) was followed by rhodamine 123 fluorescence. Although Bcl-x(L) expression did not block Fas-induced protease activation, it substantially inhibited the subsequent loss of delta psi(m) and cell death in Fas-treated cells. In contrast, zVAD-FMK blocked PARP cleavage as well as loss of delta psi(m) and cell death. Together these data demonstrate that Bcl-x(L) can maintain cell viability by preventing the loss of mitochondrial membrane potential that occurs as a consequence of ICE/Ced-3 protease activation.

References

  1. Nature. 1995 May 4;375(6526):81-3 [PMID: 7536901]
  2. Cell. 1996 Jul 12;86(1):147-57 [PMID: 8689682]
  3. J Exp Med. 1995 Aug 1;182(2):367-77 [PMID: 7629499]
  4. Genes Dev. 1995 Mar 1;9(5):509-20 [PMID: 7698643]
  5. J Exp Med. 1995 May 1;181(5):1661-72 [PMID: 7722446]
  6. J Immunol. 1996 Jul 15;157(2):512-21 [PMID: 8752896]
  7. J Exp Med. 1996 Apr 1;183(4):1533-44 [PMID: 8666911]
  8. Blood. 1996 Jul 15;88(2):386-401 [PMID: 8695785]
  9. J Biol Chem. 1995 May 26;270(21):12390-7 [PMID: 7759479]
  10. J Exp Med. 1996 Mar 1;183(3):1031-6 [PMID: 8642244]
  11. Curr Biol. 1996 May 1;6(5):555-62 [PMID: 8805273]
  12. J Exp Med. 1996 May 1;183(5):1957-64 [PMID: 8642305]
  13. Biochim Biophys Acta. 1995 Jul 17;1241(2):139-76 [PMID: 7640294]
  14. Cancer Res. 1993 Oct 1;53(19):4701-14 [PMID: 8402648]
  15. J Exp Med. 1996 Apr 1;183(4):1293-5 [PMID: 8666886]
  16. Cell. 1996 Jun 14;85(6):781-4 [PMID: 8681372]
  17. Nature. 1993 Aug 26;364(6440):806-9 [PMID: 7689176]
  18. Blood. 1995 Sep 1;86(5):1903-10 [PMID: 7655019]
  19. EMBO J. 1995 Nov 15;14(22):5579-88 [PMID: 8521815]
  20. Cell. 1996 Jun 14;85(6):817-27 [PMID: 8681377]
  21. Cell. 1996 Jun 14;85(6):803-15 [PMID: 8681376]
  22. Science. 1995 Mar 10;267(5203):1449-56 [PMID: 7533326]
  23. Nature. 1996 May 23;381(6580):335-41 [PMID: 8692274]
  24. J Exp Med. 1996 May 1;183(5):1947-51 [PMID: 8642303]
  25. Nature. 1996 Apr 25;380(6576):723-6 [PMID: 8614469]
  26. Cell. 1994 Oct 21;79(2):189-92 [PMID: 7954787]
  27. Nat Med. 1996 Jan;2(1):80-6 [PMID: 8564847]
  28. Science. 1995 Mar 10;267(5203):1445-9 [PMID: 7878463]
  29. J Biol Chem. 1993 Dec 5;268(34):25265-8 [PMID: 8244956]
  30. Nature. 1995 May 4;375(6526):78-81 [PMID: 7536900]

MeSH Term

Apoptosis
Caspase 1
Cysteine Endopeptidases
Enzyme Activation
Humans
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-bcl-2
Tumor Cells, Cultured
bcl-X Protein
fas Receptor

Chemicals

BCL2L1 protein, human
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-bcl-2
bcl-X Protein
fas Receptor
Cysteine Endopeptidases
Caspase 1

Word Cloud

Created with Highcharts 10.0.0celldeathproteasecellsactivationlossdeltapsimBcl-xLapoptosisICE/Ced-3mitochondrialmembranepotentialzVAD-FMKcleavagePARPFas-inducedcanProgrammedprovidesirreversiblemechanismeliminationexcessdamagedSeveralrecentstudiesimplicatedinterleukin1beta-convertingenzyme/Ced-3familyproteases"pointreturn"apoptoticotherssuggestedultimatedeterminanttemporalrelationshiptwoeventsroleBcl-2proteinsinhibitingstepsdefinedexamineissuescontrol-transfectedJurkatTtreatedFasantibodiespresenceabsenceICEinhibitoractivitymonitoredfollowingpolyADP-ribosepolymerasefollowedrhodamine123fluorescenceAlthoughexpressionblocksubstantiallyinhibitedsubsequentFas-treatedcontrastblockedwellTogetherdatademonstratemaintainviabilitypreventingoccursconsequenceinhibitundergone

Similar Articles

Cited By